Literature DB >> 10404160

Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells.

E Lunde1, L A Munthe, A Vabø, I Sandlie, B Bogen.   

Abstract

We have developed a strategy for improving the stimulation of T cells during immune responses by constructing recombinant antibodies that enhance the delivery of antigen to antigen-presenting cells, such as B cells. These antibodies have variable regions specific for surface molecules on B cells, and a constant region with an inserted antigen. In vitro, such antibodies make B cells approximately 1000-fold more efficient at presenting antigen and stimulating specific T cells. In vivo, the antibodies turn B cells of the spleen into potent stimulators of T cells. This approach may be useful for the generation of new vaccines.

Mesh:

Substances:

Year:  1999        PMID: 10404160     DOI: 10.1038/10883

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  14 in total

1.  The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.

Authors:  I B Rasmussen; E Lunde; T E Michaelsen; B Bogen; I Sandlie
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.

Authors:  Gunnveig Grodeland; Siri Mjaaland; Kenneth H Roux; Agnete Brunsvik Fredriksen; Bjarne Bogen
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

3.  A fusion protein derived from Moraxella catarrhalis and Neisseria meningitidis aimed for immune modulation of human B cells.

Authors:  Oindrilla Mukherjee; Birendra Singh; Burcu Bayrak; Ann-Beth Jonsson; Matthias Mörgelin; Kristian Riesbeck
Journal:  Hum Vaccin Immunother       Date:  2015-06-04       Impact factor: 3.452

4.  Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination.

Authors:  Gunnveig Grodeland; Agnete Brunsvik Fredriksen; Geir Åge Løset; Elisabeth Vikse; Lars Fugger; Bjarne Bogen
Journal:  J Immunol       Date:  2016-09-26       Impact factor: 5.422

5.  Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells.

Authors:  Heidi Cecilie Larsen Spång; Ranveig Braathen; Bjarne Bogen
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

6.  The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site.

Authors:  M M Stickler; A Reddy; J M Xiong; P R Hinton; R DuBridge; F A Harding
Journal:  Genes Immun       Date:  2011-02-17       Impact factor: 2.676

7.  T cell recognition of the dominant I-A(k)-restricted hen egg lysozyme epitope: critical role for asparagine deamidation.

Authors:  S N McAdam; B Fleckenstein; I B Rasmussen; D G Schmid; I Sandlie; B Bogen; N J Viner; L M Sollid
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

8.  Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.

Authors:  Agnete B Fredriksen; Inger Sandlie; Bjarne Bogen
Journal:  Front Oncol       Date:  2012-10-30       Impact factor: 6.244

Review 9.  Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines.

Authors:  Gunnveig Grødeland; Even Fossum; Bjarne Bogen
Journal:  Front Immunol       Date:  2015-07-20       Impact factor: 7.561

10.  An engineered non-toxic superantigen increases cross presentation of hepatitis B virus nucleocapsids by human dendritic cells.

Authors:  Julie D McIntosh; Kristy Manning; Shilpa Chokshi; Nikolai V Naoumov; John D Fraser; P Rod Dunbar; John A Taylor
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.